Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nous-209 vaccine plus pembrolizumab in microsatellite unstable colorectal cancer
2024-514723-42-00Phase 2Authorised
- Sponsor
- Nouscom
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of pembrolizumab, GAd20-209-FSP and MVA-209-FSP in colorectal cancer (CRC) (2 cohorts), sponsored by Nouscom. Primary endpoints: Objective response rate (Phase IIa) and Objective response rate (Phase IIb – Cohorts C and D). Planned start May 2022; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-514723-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514723-42-00.